Scilex reports preliminary 2022 net sales $37-42M, up 18-34% YoY; cash $1.8-2.5M

Scilex Holding Co

2022-FY EPS reported -$0.17 revenue$38,034,000

ZTlido gross sales for Dec 2022 estimated $10-12M; full-year gross sales $93-98M (up 45-53% from $63.9M in 2021).
Net sales for 2022 estimated $37-42M compared to $31.3M in 2021, growth of 18-34%.
Cash and cash equivalents as of Dec 31, 2022 estimated at $1.8-2.5M; accounts receivable $18-22M.
Results are preliminary, unaudited, and subject to change after completion of review.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Scilex Holding Co reported the one and twelve months ended December 31, 2022 results: revenue $37.0 million to $42.0 million.

Period: the one and twelve months ended December 31, 2022
Revenue: $37.0 million to $42.0 million
Result: preliminary results

Exact text from the filing

The Company estimates that: ZTlido gross sales for December 2022 were in the range of $10.0 million to $12.0 million; the gross sales for ZTlido in 2022 were in the range of $93.0 million to $98.0 million, compared to $63.9 million in 2021, representing growth in the range of 45% to 53%; net sales for 2022 were in the range of $37.0 million to $42.0 million, compared to net sales of $31.3 million in 2021, representing growth in the range of 18% to 34%; and, as of December 31, 2022, the Company’s cash and cash equivalents were in the range of $1.8 million to $2.5 million, and the Company’s accounts receivables were in the range of $18.0 million to $22.0 million.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Scilex Holding Co filing history →

Source: SEC EDGAR

accession 0001193125-23-000315

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.